Nouscom — viral-vector vaccines including the off-the-shelf NOUS-209 for MSI-high tumors and personalized programs.
[ACTIVE_NOT_RECRUITING · PHASE1, PHASE2 · National Cancer Institute (NCI)] This phase Ib/II trial evaluates the safety and effect of the Nous-209 vaccine in Lynch syndrome patients. Lynch syndrome is an inherited disorder in which affected individuals have a higher-than-normal ch…
Molecular characterization of precancerous lesions in Lynch syndrome carriers confirms that Nous-209 target mutations occur early in adenoma progression, supporting the vaccine's preventive potential. The study found that Nous-209 mutation counts correlate strongly with microsatellite instability status, with dMMR/MSI-H lesions harboring the highest burden, validating the target population for this NCI-sponsored Phase Ib/II trial.
The NCI is running a Phase Ib/II trial of the Nous-209 vaccine in Lynch syndrome patients to evaluate safety, immune response, and potential effects on polyp or tumor development. The vaccine consists of man-made copies of neoantigens generated by mismatch repair errors, targeting the high-risk colorectal cancer population associated with inherited genetic variants.
Nature publishes results from a Phase 1b/2 trial of the Nous-209 neoantigen vaccine for cancer prevention in Lynch syndrome carriers. The publication provides clinical data on the vaccine's ability to intercept cancer development in genetically predisposed individuals, a key differentiator in the neoantigen landscape.
Oncodaily highlights a new paper on Nous-209, a neoantigen vaccine designed for cancer interception in Lynch syndrome carriers. This focus on prevention in high-risk genetic populations signals a strategic expansion of neoantigen vaccines beyond therapeutic treatment to early-stage disease modification.